Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants

Autor:	Doris Makari, Leonard B. Weiner, John P. DeVincenzo, Christopher S. Ambrose
Rok vydání:	2016
Předmět:	Palivizumab Pediatrics medicine.medical_specialty palivizumab Immunology Short Report Context (language use) Infant Premature Diseases Respiratory Syncytial Virus Infections RSV hospitalization Antiviral Agents Virus 03 medical and health sciences 0302 clinical medicine Risk Factors 030225 pediatrics Humans Immunology and Allergy Medicine NVSN 030212 general & internal medicine Respiratory system Disease burden Pharmacology Vaccines business.industry Incidence Incidence (epidemiology) Infant Newborn Network data RSV Infant Social Support Gestational age United States Hospitalization Respiratory Syncytial Virus Human Epidemiological Monitoring Female preterm business Infant Premature medicine.drug
Zdroj:	Human Vaccines & Immunotherapeutics
ISSN:	2164-554X 2164-5515
DOI:	10.1080/21645515.2015.1115936
Popis:	In July 2014, the Committee on Infectious Diseases (COID) updated their guidance on the use of palivizumab, recommending against use in preterm infants 29 to 35 weeks' gestational age (wGA). A primary data source cited to support this significant change was the low respiratory syncytial virus (RSV) hospitalization rate observed in the subpopulation of preterm (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b0f2ed4031f96f3521d5907f5216c8 https://doi.org/10.1080/21645515.2015.1115936 Zobrazit plný text záznamu